

**In the Specification**

Before the heading of "Background of the Invention," please insert:

**CROSS REFERENCE**

This is a divisional application of application serial number 09/851,877, filed on May 9, 2001.

Please amend the first paragraph of page 5 as follows:

A variety of drug classes and therapeutic substances may be used in accordance with the present disclosure. For example, therapeutic substances or agents may include, but are not limited to, antineoplastic, antimitotic, antiinflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antiproliferative, antibiotic, antioxidant, and antiallergic substances as well as combinations thereof. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL<sup>®</sup> by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere<sup>®</sup>, from Aventis S.A., Frankfurt, Germany), methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, actinomycin-D, doxorubicin hydrochloride (e.g. Adriamycin<sup>®</sup> from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin<sup>®</sup> from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as

Angiomax <sup>TM</sup> (Biogen, Inc., Cambridge, Mass.)\_ Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (*e.g.*, Capoten<sup>®</sup> and Capozide<sup>®</sup> from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (*e.g.* Prinivil<sup>®</sup> and Prinzide<sup>®</sup> from Merck & Co., Inc., Whitehouse Station, NJ)[[;]], calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor<sup>®</sup> from Merck & Co., Inc., Whitehouse Station, NJ), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, and dexamethasone.

Please amend the last paragraph of page 15, continuing to page 16 as follows:

With the use of one of the aforementioned thermoplastic polymers, the use of initiators may be required. By way of example, epoxy systems consisting of diglycidyl ether of bisphenol A resins can be cured with amine curatives, thermoset polyurethane prepolymers can be cured with polyols, polyamines, or water (moisture), and acrylated urethane can be cured with UV light. Further discussion of polymers, solvents, wetting fluids and initiators are disclosed in commonly assigned U.S. Application No. 09/750,595, (~~Attorney Docket No. 16315v~~), entitled "Coating for

Implantable Devices and a Method of Forming the Same”, filed December 28, 2000, which is  
herein incorporated by reference for all purposes.